Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  HIV Infection

  Free Subscription


13.03.2017

6 AIDS
2 AIDS Res Hum Retroviruses
1 Antivir Ther
1 BMC Neurol
1 BMC Pediatr
6 J Acquir Immune Defic Syndr
1 J Immunol
4 J Virol
2 Lancet
13 Lancet HIV
2 Lancet Infect Dis
3 N Engl J Med
1 Neurology
14 PLoS One
1 PLoS Pathog
3 Vaccine


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AIDS


  1. Timing of combined antiretroviral treatment initiation in male and female migrants living with HIV in Western Europe.
    AIDS. 2017;31:835-846.
    PubMed     Text format     Abstract available

  2. MAHALINGASIVAM V, Gathogo E, Bramham K, Post FA, et al
    Successful pregnancy in an HIV-positive kidney transplant recipient.
    AIDS. 2017;31:872-873.
    PubMed     Text format    

  3. JINDAL AK, Ahluwalia J, Sharma A, Dhawan S, et al
    HIV-infected children with hepatomegaly and ascites: is there something more than an infection?
    AIDS. 2017;31:870-872.
    PubMed     Text format    

  4. WINCKELMANN A, Barton K, Hiener B, Schlub TE, et al
    Romidepsin-induced HIV-1 viremia during effective antiretroviral therapy contains identical viral sequences with few deleterious mutations.
    AIDS. 2017;31:771-779.
    PubMed     Text format     Abstract available

  5. PUSKAS CM, Kaida A, Miller CL, Zhang W, et al
    The adherence gap: a longitudinal examination of men's and women's antiretroviral therapy adherence in British Columbia, 2000-2014.
    AIDS. 2017;31:827-833.
    PubMed     Text format     Abstract available

  6. GOEDERT JJ
    The microbiota and HIV: shedding light on dark matters.
    AIDS. 2017;31:863-865.
    PubMed     Text format    


    AIDS Res Hum Retroviruses

  7. MENESES GC, Cavalcante MG, Da Silva Junior G, Martins AM, et al
    Endothelial glycocalyx damage and renal dysfunction in HIV patients receiving combined antiretroviral therapy.
    AIDS Res Hum Retroviruses. 2017 Mar 6. doi: 10.1089/AID.2016.0284.
    PubMed     Text format     Abstract available

  8. TREVINO A, Aguilera A, Rodriguez-Iglesias MA, Hernandez A, et al
    HTLV infection in HCV-antibody positive patients in Spain.
    AIDS Res Hum Retroviruses. 2017 Mar 7. doi: 10.1089/AID.2016.0323.
    PubMed     Text format     Abstract available


    Antivir Ther

  9. LALLEY-CHARECZKO L, Clark D, Zuppa AF, Moorthy G, et al
    A case study of chewed Truvada(R) for PrEP maintaining protective drug levels as measured by a novel urine tenofovir assay.
    Antivir Ther. 2017 Mar 6. doi: 10.3851/IMP3151.
    PubMed     Text format     Abstract available


    BMC Neurol

  10. PACKHAM TL, Cappelleri JC, Sadosky A, MacDermid JC, et al
    Measurement properties of painDETECT: Rasch analysis of responses from community-dwelling adults with neuropathic pain.
    BMC Neurol. 2017;17:48.
    PubMed     Text format     Abstract available


    BMC Pediatr

  11. SUTCLIFFE CG, Thuma PE, van Dijk JH, Sinywimaanzi K, et al
    Use of mobile phones and text messaging to decrease the turnaround time for early infant HIV diagnosis and notification in rural Zambia: an observational study.
    BMC Pediatr. 2017;17:66.
    PubMed     Text format     Abstract available


    J Acquir Immune Defic Syndr

  12. PUHR R, Kumarasamy N, Ly PS, Ng OT, et al
    HIV and Aging: Demographic Change in the Asia-Pacific Region.
    J Acquir Immune Defic Syndr. 2017;74:e146-e148.
    PubMed     Text format    

  13. GWADZ M, Cleland CM, Perlman DC, Hagan H, et al
    Public Health Benefit of Peer-Referral Strategies for Detecting Undiagnosed HIV Infection Among High-Risk Heterosexuals in New York City.
    J Acquir Immune Defic Syndr. 2017;74:499-507.
    PubMed     Text format     Abstract available

  14. HALL EW, Ricca AV, Khosropour CM, Sullivan PS, et al
    Capturing HIV incidence among MSM through at-home and self-reported facility-based testing.
    J Acquir Immune Defic Syndr. 2017 Mar 8. doi: 10.1097/QAI.0000000000001338.
    PubMed     Text format    

  15. WOHL DA, Golin CE, Knight K, Gould M, et al
    A Randomized Controlled Trial of an Intervention to Maintain Suppression of HIV Viremia Following Prison Release: The imPACT Trial.
    J Acquir Immune Defic Syndr. 2017 Mar 8. doi: 10.1097/QAI.0000000000001337.
    PubMed     Text format     Abstract available

  16. RAFFI F, Orkin C, Clarke A, Slama L, et al
    Long-term (96-week) Efficacy and Safety After Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) in HIV-infected, Virologically Suppressed Adults.
    J Acquir Immune Defic Syndr. 2017 Mar 6. doi: 10.1097/QAI.0000000000001344.
    PubMed     Text format     Abstract available

  17. LACOMBE K, Fontaine H, Dhiver C, Metivier S, et al
    Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Co-Infected Patients With Advanced Liver Disease in a French Early-Access Cohort.
    J Acquir Immune Defic Syndr. 2017 Mar 6. doi: 10.1097/QAI.0000000000001342.
    PubMed     Text format     Abstract available


    J Immunol

  18. SCHWARTZ JA, Clayton KL, Mujib S, Zhang H, et al
    Tim-3 is a Marker of Plasmacytoid Dendritic Cell Dysfunction during HIV Infection and Is Associated with the Recruitment of IRF7 and p85 into Lysosomes and with the Submembrane Displacement of TLR9.
    J Immunol. 2017 Mar 6. pii: 1601298. doi: 10.4049/jimmunol.1601298.
    PubMed     Text format     Abstract available


    J Virol

  19. MARNO KM, O'Sullivan E, Jones CE, Diaz-Delfin J, et al
    RNA-associated Early-stage Anti-viral Factor (REAF) is a major component of LV2 restriction.
    J Virol. 2017 Mar 8. pii: JVI.01228-16. doi: 10.1128/JVI.01228.
    PubMed     Text format     Abstract available

  20. ZHANG X, Zhou T, Yang J, Lin Y, et al
    Identification of SERINC5-001 as the Predominant Spliced Isoform for HIV-1 Restriction.
    J Virol. 2017 Mar 8. pii: JVI.00137-17. doi: 10.1128/JVI.00137.
    PubMed     Text format     Abstract available

  21. CHUANG GY, Geng H, Pancera M, Xu K, et al
    Structure-Based Design of a Soluble Prefusion-Closed HIV-1-Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity.
    J Virol. 2017 Mar 8. pii: JVI.02268-16. doi: 10.1128/JVI.02268.
    PubMed     Text format     Abstract available

  22. GAO J, Hay TJ, Banfield BW
    The Product of the Herpes Simplex Virus Type 2 UL16 Gene is Critical for the Egress of Capsids from the Nuclei of Infected Cells.
    J Virol. 2017 Mar 8. pii: JVI.00350-17. doi: 10.1128/JVI.00350.
    PubMed     Text format     Abstract available


    Lancet

  23. MENDENHALL E, Kohrt BA, Norris SA, Ndetei D, et al
    Non-communicable disease syndemics: poverty, depression, and diabetes among low-income populations.
    Lancet. 2017;389:951-963.
    PubMed     Text format     Abstract available

  24. MOHAMMADI D
    Growing older with HIV in the UK.
    Lancet. 2017;389:894-895.
    PubMed     Text format    


    Lancet HIV

  25. BRUGGEMANS A, Debyser Z
    Tenofovir prodrugs: similar but not the same.
    Lancet HIV. 2017 Mar 1. pii: S2352-3018(17)30033.
    PubMed     Text format    

  26. FRANCO-PAREDES C, Chastain DB, Ezigbo C, Callins KR, et al
    Reducing transmission of HIV in southeastern USA.
    Lancet HIV. 2017;4:e101-e102.
    PubMed     Text format    

  27. HOGG RS, Eyawo O, Collins AB, Zhang W, et al
    Health-adjusted life expectancy in HIV-positive and HIV-negative men and women in British Columbia, Canada: a population-based observational cohort study.
    Lancet HIV. 2017 Mar 2. pii: S2352-3018(17)30029.
    PubMed     Text format     Abstract available

  28. PERAZZO H, Luz PM
    Liver disease and healthy life-expectancy with HIV.
    Lancet HIV. 2017 Mar 2. pii: S2352-3018(17)30030.
    PubMed     Text format    

  29. ORKIN C, DeJesus E, Ramgopal M, Crofoot G, et al
    Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
    Lancet HIV. 2017 Mar 1. pii: S2352-3018(17)30031.
    PubMed     Text format     Abstract available

  30. DEJESUS E, Ramgopal M, Crofoot G, Ruane P, et al
    Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, n
    Lancet HIV. 2017 Mar 1. pii: S2352-3018(17)30032.
    PubMed     Text format     Abstract available

  31. WIRTZ AL, Trapence G, Kamba D, Gama V, et al
    Geographical disparities in HIV prevalence and care among men who have sex with men in Malawi: results from a multisite cross-sectional survey.
    Lancet HIV. 2017 Feb 27. pii: S2352-3018(17)30042.
    PubMed     Text format     Abstract available

  32. GRAHAM SM, Harper GW
    Improving HIV prevention and care for African GBMSM.
    Lancet HIV. 2017 Feb 27. pii: S2352-3018(17)30020.
    PubMed     Text format    

  33. KAZATCHKINE M
    Towards a new health diplomacy in eastern Ukraine.
    Lancet HIV. 2017;4:e99-e101.
    PubMed     Text format    

  34. THE LANCET HIV
    Gag rule at odds with progress in HIV/AIDS.
    Lancet HIV. 2017;4:e93.
    PubMed     Text format    

  35. CLIFFORD GM, Lise M, Franceschi S, Scherrer AU, et al
    CD4/CD8 ratio and lung cancer risk.
    Lancet HIV. 2017;4:e103.
    PubMed     Text format    

  36. SIGEL K, Dubrow R
    CD4/CD8 ratio and lung cancer risk - Authors' reply.
    Lancet HIV. 2017;4:e103-e104.
    PubMed     Text format    


  37. Correction to Lancet HIV 2017; 4: e122-33.
    Lancet HIV. 2017;4:e102.
    PubMed     Text format    


    Lancet Infect Dis

  38. DE BRUIN M, Oberje EJ, Viechtbauer W, Nobel HE, et al
    Effectiveness and cost-effectiveness of a nurse-delivered intervention to improve adherence to treatment for HIV: a pragmatic, multicentre, open-label, randomised clinical trial.
    Lancet Infect Dis. 2017 Mar 2. pii: S1473-3099(16)30534.
    PubMed     Text format     Abstract available

  39. SIMONI JM, Aunon FM, Kemp CG, Kutner BA, et al
    Implementation research on HIV adherence interventions: no time to wait.
    Lancet Infect Dis. 2017 Mar 2. pii: S1473-3099(17)30106.
    PubMed     Text format    


    N Engl J Med


  40. Dapivirine Vaginal Ring for HIV-1 Prevention.
    N Engl J Med. 2017;376:995-6.
    PubMed     Text format    

  41. SEIDMAN D, Weber S, Aaron E
    Dapivirine Vaginal Ring for HIV-1 Prevention.
    N Engl J Med. 2017;376:995.
    PubMed     Text format    

  42. WINCESLAUS SJ
    Dapivirine Vaginal Ring for HIV-1 Prevention.
    N Engl J Med. 2017;376:994-5.
    PubMed     Text format    


    Neurology

  43. COLE JH, Underwood J, Caan MW, De Francesco D, et al
    Increased brain-predicted aging in treated HIV disease.
    Neurology. 2017 Mar 3. pii: 10.1212/WNL.0000000000003790.
    PubMed     Text format     Abstract available


    PLoS One

  44. GOTT C, Gates T, Dermody N, Brew BJ, et al
    Cognitive change trajectories in virally suppressed HIV-infected individuals indicate high prevalence of disease activity.
    PLoS One. 2017;12:e0171887.
    PubMed     Text format     Abstract available

  45. PUTTKAMMER N, Domercant JW, Adler M, Yuhas K, et al
    ART attrition and risk factors among Option B+ patients in Haiti: A retrospective cohort study.
    PLoS One. 2017;12:e0173123.
    PubMed     Text format     Abstract available

  46. KEDDY KH, Takuva S, Musekiwa A, Puren AJ, et al
    An association between decreasing incidence of invasive non-typhoidal salmonellosis and increased use of antiretroviral therapy, Gauteng Province, South Africa, 2003-2013.
    PLoS One. 2017;12:e0173091.
    PubMed     Text format     Abstract available

  47. POLLACK TM, Duong HT, Pham TT, Do CD, et al
    Cigarette smoking is associated with high HIV viral load among adults presenting for antiretroviral therapy in Vietnam.
    PLoS One. 2017;12:e0173534.
    PubMed     Text format     Abstract available

  48. LI R, Wang H, Pan X, Ma Q, et al
    Prevalence of condomless anal intercourse and recent HIV testing and their associated factors among men who have sex with men in Hangzhou, China: A respondent-driven sampling survey.
    PLoS One. 2017;12:e0167730.
    PubMed     Text format     Abstract available

  49. RODRIGUEZ-ARBOLI E, Mwamelo K, Kalinjuma AV, Furrer H, et al
    Incidence and risk factors for hypertension among HIV patients in rural Tanzania - A prospective cohort study.
    PLoS One. 2017;12:e0172089.
    PubMed     Text format     Abstract available

  50. HU H, Yan H, Liu X, Xu X, et al
    Trends in late HIV diagnosis among men who have sex with men in Jiangsu province, China: Results from four consecutive community-based surveys, 2011-2014.
    PLoS One. 2017;12:e0172664.
    PubMed     Text format     Abstract available

  51. KNOPF AS, McNealy KR, Al-Khattab H, Carter-Harris L, et al
    Sexual learning among East African adolescents in the context of generalized HIV epidemics: A systematic qualitative meta-synthesis.
    PLoS One. 2017;12:e0173225.
    PubMed     Text format     Abstract available

  52. MULLIN JM, Diguilio KM, Valenzano MC, Deis R, et al
    Zinc reduces epithelial barrier compromise induced by human seminal plasma.
    PLoS One. 2017;12:e0170306.
    PubMed     Text format     Abstract available

  53. CHAPMAN R, Jongwe TI, Douglass N, Chege G, et al
    Heterologous prime-boost vaccination with DNA and MVA vaccines, expressing HIV-1 subtype C mosaic Gag virus-like particles, is highly immunogenic in mice.
    PLoS One. 2017;12:e0173352.
    PubMed     Text format     Abstract available

  54. WINKLER M, Gartner S, Wrensch F, Krawczak M, et al
    Rhesus macaque IFITM3 gene polymorphisms and SIV infection.
    PLoS One. 2017;12:e0172847.
    PubMed     Text format     Abstract available

  55. ROSS I, Mejia C, Melendez J, Chan PA, et al
    Awareness and attitudes of pre-exposure prophylaxis for HIV prevention among physicians in Guatemala: Implications for country-wide implementation.
    PLoS One. 2017;12:e0173057.
    PubMed     Text format     Abstract available

  56. CLAASSENS MM, van Schalkwyk C, Floyd S, Ayles H, et al
    Symptom screening rules to identify active pulmonary tuberculosis: Findings from the Zambian South African Tuberculosis and HIV/AIDS Reduction (ZAMSTAR) trial prevalence surveys.
    PLoS One. 2017;12:e0172881.
    PubMed     Text format     Abstract available

  57. QUATREMERE G, Guiguet M, Girardi P, Liaud MN, et al
    How are women living with HIV in France coping with their perceived side effects of antiretroviral therapy? Results from the EVE study.
    PLoS One. 2017;12:e0173338.
    PubMed     Text format     Abstract available


    PLoS Pathog

  58. BEAUPARLANT D, Rusert P, Magnus C, Kadelka C, et al
    Delineating CD4 dependency of HIV-1: Adaptation to infect low level CD4 expressing target cells widens cellular tropism but severely impacts on envelope functionality.
    PLoS Pathog. 2017;13:e1006255.
    PubMed     Text format     Abstract available


    Vaccine

  59. SEIB K, Pollard AJ, de Wals P, Andrews RM, et al
    Policy making for vaccine use as a driver of vaccine innovation and development in the developed world.
    Vaccine. 2017;35:1380-1389.
    PubMed     Text format     Abstract available

  60. SETH L, Bingham Ferlez KM, Kaba SA, Musser DM, et al
    Development of a self-assembling protein nanoparticle vaccine targeting Plasmodium falciparum Circumsporozoite Protein delivered in three Army Liposome Formulation adjuvants.
    Vaccine. 2017 Mar 5. pii: S0264-410X(17)30243.
    PubMed     Text format     Abstract available

  61. GIERSING BK, Vekemans J, Nava S, Kaslow DC, et al
    Report from the World Health Organization's third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8-10th June 2016.
    Vaccine. 2017 Mar 2. pii: S0264-410X(16)31205.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO HIV Infection is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: